Stay updated with breaking news from John Koconis. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Timber Pharmaceuticals Announces Publication of Results from Phase 2b CONTROL Study of FDA-Designated Breakthrough Therapy TMB-001 in the Journal of the American Academy of Dermatology - read this article along with other careers information, tips and advice on BioSpace
Timber Enrolls First Patients in Phase 3 ASCEND Clinical Trial after Receiving Breakthrough Designation from FDA for Lead Asset TMB-001 BASKING...
Timber Pharmaceuticals has enrolled its first four patients in the phase 3 trial of its topical isotretinoin formula for the treatment of congenital ichthyosis, the company announced in a press release.TMB-001 0.05% is formulated using Timber’s patented IPEG delivery system and was granted an orphan drug designation by the FDA.
Press release content from NewMediaWire. The AP news staff was not involved in its creation.
Lead Asset TMB-001 Receives Fast Track Designation in Advance of Phase 3 Study Initiation by June 30th, 2022 BASKING RIDGE, NJ, May 12, 2022 (GLOBE...